REGN vs. VEEV: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at REGN and VEEV, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | REGN | VEEV |
|---|---|---|
| Company Name | Regeneron Pharmaceuticals, Inc. | Veeva Systems Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Technology |
| Market Capitalization | 62.50 billion USD | 48.07 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | April 2, 1991 | October 16, 2013 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of REGN and VEEV by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | REGN | VEEV |
|---|---|---|
| 5-Day Price Return | -2.55% | 7.19% |
| 13-Week Price Return | 7.10% | 3.45% |
| 26-Week Price Return | -12.16% | 26.44% |
| 52-Week Price Return | -46.08% | 41.29% |
| Month-to-Date Return | -3.17% | 10.66% |
| Year-to-Date Return | -21.07% | 41.69% |
| 10-Day Avg. Volume | 1.22M | 1.29M |
| 3-Month Avg. Volume | 1.13M | 1.44M |
| 3-Month Volatility | 28.52% | 26.99% |
| Beta | 0.30 | 0.98 |
Profitability
Return on Equity (TTM)
REGN
15.11%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
In the upper quartile for the Biotechnology industry, REGN’s Return on Equity of 15.11% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
VEEV
13.40%
Health Care Technology Industry
- Max
- 48.09%
- Q3
- 41.80%
- Median
- 18.17%
- Q1
- 11.64%
- Min
- 11.05%
VEEV’s Return on Equity of 13.40% is on par with the norm for the Health Care Technology industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
REGN
31.37%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
A Net Profit Margin of 31.37% places REGN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
VEEV
27.29%
Health Care Technology Industry
- Max
- 52.24%
- Q3
- 49.15%
- Median
- 33.59%
- Q1
- 16.86%
- Min
- 13.38%
VEEV’s Net Profit Margin of 27.29% is aligned with the median group of its peers in the Health Care Technology industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
REGN
27.02%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
An Operating Profit Margin of 27.02% places REGN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
VEEV
26.93%
Health Care Technology Industry
- Max
- 74.05%
- Q3
- 65.56%
- Median
- 33.50%
- Q1
- 22.83%
- Min
- 21.46%
VEEV’s Operating Profit Margin of 26.93% is around the midpoint for the Health Care Technology industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | REGN | VEEV |
|---|---|---|
| Return on Equity (TTM) | 15.11% | 13.40% |
| Return on Assets (TTM) | 11.81% | 10.96% |
| Net Profit Margin (TTM) | 31.37% | 27.29% |
| Operating Profit Margin (TTM) | 27.02% | 26.93% |
| Gross Profit Margin (TTM) | 86.46% | 75.59% |
Financial Strength
Current Ratio (MRQ)
REGN
4.60
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
REGN’s Current Ratio of 4.60 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
VEEV
5.57
Health Care Technology Industry
- Max
- 6.49
- Q3
- 6.49
- Median
- 6.02
- Q1
- 3.62
- Min
- 2.96
VEEV’s Current Ratio of 5.57 aligns with the median group of the Health Care Technology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
REGN
0.09
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
REGN’s Debt-to-Equity Ratio of 0.09 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
VEEV
0.00
Health Care Technology Industry
- Max
- 0.14
- Q3
- 0.10
- Median
- 0.01
- Q1
- 0.00
- Min
- 0.00
Falling into the lower quartile for the Health Care Technology industry, VEEV’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
REGN
243.95
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
With an Interest Coverage Ratio of 243.95, REGN demonstrates a superior capacity to service its debt, placing it well above the typical range for the Biotechnology industry. This stems from either robust earnings or a conservative debt load.
VEEV
169.00
Health Care Technology Industry
- Max
- 224.12
- Q3
- 224.12
- Median
- 219.00
- Q1
- 219.00
- Min
- 219.00
VEEV’s Interest Coverage Ratio of 169.00 is below the typical range for the Health Care Technology industry. This suggests a weaker ability to meet debt obligations compared to its peers and may indicate a higher level of financial risk.
Financial Strength at a Glance
| Symbol | REGN | VEEV |
|---|---|---|
| Current Ratio (MRQ) | 4.60 | 5.57 |
| Quick Ratio (MRQ) | 3.78 | 5.48 |
| Debt-to-Equity Ratio (MRQ) | 0.09 | 0.00 |
| Interest Coverage Ratio (TTM) | 243.95 | 169.00 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
REGN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
VEEV
0.00%
Health Care Technology Industry
- Max
- 0.89%
- Q3
- 0.70%
- Median
- 0.15%
- Q1
- 0.04%
- Min
- 0.00%
VEEV currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
REGN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
VEEV
0.00%
Health Care Technology Industry
- Max
- 101.92%
- Q3
- 87.10%
- Median
- 42.63%
- Q1
- 10.66%
- Min
- 0.00%
VEEV has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | REGN | VEEV |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
REGN
13.97
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
In the lower quartile for the Biotechnology industry, REGN’s P/E Ratio of 13.97 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
VEEV
59.31
Health Care Technology Industry
- Max
- 280.41
- Q3
- 225.12
- Median
- 59.01
- Q1
- 44.08
- Min
- 39.20
VEEV’s P/E Ratio of 59.31 is within the middle range for the Health Care Technology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
REGN
4.38
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
In the lower quartile for the Biotechnology industry, REGN’s P/S Ratio of 4.38 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
VEEV
16.18
Health Care Technology Industry
- Max
- 146.49
- Q3
- 115.78
- Median
- 19.83
- Q1
- 7.94
- Min
- 5.25
VEEV’s P/S Ratio of 16.18 aligns with the market consensus for the Health Care Technology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
REGN
1.89
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
REGN’s P/B Ratio of 1.89 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
VEEV
7.00
Health Care Technology Industry
- Max
- 115.01
- Q3
- 89.07
- Median
- 9.11
- Q1
- 4.04
- Min
- 3.06
VEEV’s P/B Ratio of 7.00 is within the conventional range for the Health Care Technology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | REGN | VEEV |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 13.97 | 59.31 |
| Price-to-Sales Ratio (TTM) | 4.38 | 16.18 |
| Price-to-Book Ratio (MRQ) | 1.89 | 7.00 |
| Price-to-Free Cash Flow Ratio (TTM) | 17.52 | 36.17 |